A Food and Drug Administration advisory committee on Friday recommended allowing two more unproven peptides to be compounded, capping a two-day meeting that raised questions about whether the agency was weakening the guardrails designed to keep untested drugs from reaching patients.
Subscribe to read this story ad-free
Get unlimited access to ad-free articles and exclusive content.
